Blueprint Medicines Corporation (NASDAQ: BPMC), a US-based global precision therapy company that said it invents life-changing therapies for people with cancer and blood disorders, announced on Tuesday that the US Food and Drug Administration (FDA) has withdrawn a partial clinical hold on the Phase 1/2 VELA trial of BLU-222.
The company announced on 10 February 2023 that the FDA had placed a partial clinical hold on the VELA trial because of reported visual adverse events, which included transient, reversible episodes of light sensitivity and blurred vision, observed in a limited number of patients. Subjects already enrolled in the trial have continued receiving the study drug.
With the removal of the partial clinical hold, the company is working with trial sites to reinitiate patient enrolment.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval